AstraZeneca lung cancer drug approved in China
AstraZeneca
10,024.00p
08:35 15/11/24
-2.60%
-268.00p
Pharmaceutical company AstraZeneca said its drug to treat extensive-stage small cell lung cancer had been approved in China.
FTSE 100
8,044.51
08:35 15/11/24
n/a
n/a
FTSE 350
4,444.55
08:35 15/11/24
n/a
n/a
FTSE All-Share
4,403.01
08:35 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,303.24
08:35 15/11/24
-2.48%
-491.72
The approval by China's National Medical Products Administration was based on positive results from the CASPIAN Phase 3 trial, which showed that Imfinzi plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement in overall survival versus chemotherapy alone”.
“In addition, results from the China cohort of patients were consistent with the global results,” Astra said on Monday.